Vera Therapeutics price target raised to $70 from $65 at BofA
BofA raised the firm's price target on Vera Therapeutics to $70 from $65 and keeps a Buy rating on the shares following Trutakna's conditional FDA approval for the treatment of immunoglobulin A nephropathy. Trutakna's IgAN label includes "nothing surprising" and looks "more-or-less in-line with first-in-class Otsuka's